ProPhase (PRPH): רווח נקי למניה (EPS TTM)

ProPhase Labs, Inc. (PRPH) is expanding its B2B segment through the implementation of Nebula genomic sequencing and LineaRx diagnostics. This 12-month net income per share chart illustrates the dynamics of this process, where 0.00 captures a new level. Stability is ensured by the balance between laboratory tests and dietary supplements, while growth is supported by nutraceutical sales and the development of genetic research.

ProPhase Labs, Inc. (PRPH) is building a foundation for profit scaling through diversification into genomic research and high-throughput laboratories. This trend is captured by the rolling per-share profit indicator. The EPS TTM metric measures the net income per share over the past year, filtering out market noise. In an environment of expensive borrowing, this indicator confirms the business's capacity for autonomous survival. The upward trend on the chart reflects capital resilience and efficient asset management.